Movement disorders in spinocerebellar ataxias

Movement Disorders

Volumn 26, Issue 5, 2011, Pages 792-800

  van Gaalen, Judith ^a   Giunti, Paola ^b   Van de Warrenburg, Bart P ^a  

^a RADBOUD UNIVERSITY   (Netherlands)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Basal ganglia; Cerebellar ataxia; Motor system; Movement disorders; Spinocerebellar ataxias

Indexed keywords

BOTULINUM TOXIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; LEVODOPA;

BRAIN DEPTH STIMULATION; CEREBELLAR ATAXIA; CEREBELLUM ATROPHY; CHOREA; CLINICAL FEATURE; CORPUS STRIATUM; DYSKINESIA; DYSTONIA; ELECTROENCEPHALOGRAM; ESSENTIAL TREMOR; EXTRAPYRAMIDAL SYMPTOM; FOCAL DYSTONIA; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE; GLOBUS PALLIDUS; HAND TREMOR; HAPLOTYPE; HUMAN; HUNTINGTON CHOREA; LOW DRUG DOSE; MOTOR CORTEX; MOTOR DYSFUNCTION; MUTATIONAL ANALYSIS; MYOCLONUS; NEUROIMAGING; NEUROPATHOLOGY; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; REVIEW; SPINOCEREBELLAR DEGENERATION; SUBSTANTIA NIGRA; TREATMENT RESPONSE;

HUMANS; MOVEMENT DISORDERS; SPINOCEREBELLAR ATAXIAS;

EID: 79955085928     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23584     Document Type: Review

References (111)

1. Schmitz-Hubsch T, Coudert M, Bauer P, et al. Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms. Neurology 2008; 71: 982-989.
2. Schols L, Amoiridis G, Buttner T, Przuntek H, Epplen JT, Riess O. Autosomal dominant cerebellar ataxia: phenotypic differences in genetically defined subtypes? Ann Neurol 1997; 42: 924-932.
3. Cancel G, Durr A, Didierjean O, et al. Molecular and clinical correlations in spinocerebellar ataxia 2: a study of 32 families. Hum Mol Genet 1997; 6: 709-715.
4. Yamashita I, Sasaki H, Yabe I, et al. A novel locus for dominant cerebellar ataxia (SCA14) maps to a 10.2-cM interval flanked by D19S206 and D19S605 on chromosome 19q13.4-qter. Ann Neurol 2000; 48: 156-163.
5. Visser JE, Bloem BR, van De Warrenburg BP. PRKCG mutation (SCA-14) causing a Ramsay Hunt phenotype. Mov Disord 2007; 22: 1024-1026.
6. Verbeek DS, Warrenburg BP, Hennekam FA, et al. Gly118Asp is a SCA14 founder mutation in the Dutch ataxia population. Hum Genet 2005; 117: 88-91.
7. Schelhaas HJ, Ippel PF, Hageman G, Sinke RJ, van der Laan EN, Beemer FA. Clinical and genetic analysis of a four-generation family with a distinct autosomal dominant cerebellar ataxia. J Neurol 2001; 248: 113-120.
8. Mariotti C, Alpini D, Fancellu R, et al. Spinocerebellar ataxia type 17 (SCA17): oculomotor phenotype and clinical characterization of 15 Italian patients. J Neurol 2007; 254: 1538-1546.
9. Hagenah JM, Zuhlke C, Hellenbroich Y, Heide W, Klein C. Focal dystonia as a presenting sign of spinocerebellar ataxia 17. Mov Disord 2004; 19: 217-220.
10. Boesch SM, Muller J, Wenning GK, Poewe W. Cervical dystonia in spinocerebellar ataxia type 2: clinical and polymyographic findings. J Neurol Neurosurg Psychiatry 2007; 78: 520-522.
11. Muzaimi MB, Wiles CM, Robertson NP, Ravine D, Compston DA. Task specific focal dystonia: a presentation of spinocerebellar ataxia type 6. J Neurol Neurosurg Psychiatry 2003; 74: 1444-1445.
12. van De Warrenburg BP, Verbeek DS, Piersma SJ, et al. Identification of a novel SCA14 mutation in a Dutch autosomal dominant cerebellar ataxia family. Neurology 2003; 61: 1760-1765.
13. Giunti P, Sabbadini G, Sweeney MG, et al. The role of the SCA2 trinucleotide repeat expansion in 89 autosomal dominant cerebellar ataxia families. Frequency, clinical and genetic correlates. Brain 1998; 121: 459-467.
14. Zarubova K, Ruzicka E. Cervical dystonia in spinocerebellar ataxia type 2. Mov Disord 2006; 21: 1295-1296.
15. Nandagopal R, Moorthy SG. Dramatic levodopa responsiveness of dystonia in a sporadic case of spinocerebellar ataxia type 3. Postgrad Med J 2004; 80: 363-365.
16. Kitahara M, Shimohata T, Tokunaga J, Nishizawa M. Cervical dystonia associated with spinocerebellar ataxia type 2 successfully treated with levodopa: a case report. Mov Disord 2009; 24: 2163-2164.
17. Munchau A, Dressler D, Bhatia KP, Vogel P, Zuhlke C. Machado-Joseph disease presenting as severe generalised dystonia in a German patient. J Neurol 1999; 246: 840-842.
18. Sethi KD, Jankovic J. Dystonia in spinocerebellar ataxia type 6. Mov Disord 2002; 17: 150-153.
19. Wilder-Smith E, Tan EK, Law HY, Zhao Y, Ng I, Wong MC. Spinocerebellar ataxia type 3 presenting as an L-DOPA responsive dystonia phenotype in a Chinese family. J Neurol Sci 2003; 213: 25-28.
20. Jardim LB, Pereira ML, Silveira I, Ferro A, Sequeiros J, Giugliani R. Neurologic findings in Machado-Joseph disease: relation with disease duration, subtypes, and (CAG)n. Arch Neurol 2001; 58: 899-904.
21. Stevanin G, Fujigasaki H, Lebre AS, et al. Huntington's disease-like phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genes. Brain 2003; 126: 1599-1603.
22. Bauer P, Laccone F, Rolfs A, et al. Trinucleotide repeat expansion in SCA17/TBP in white patients with Huntington's disease-like phenotype. J Med Genet 2004; 41: 230-232.
23. Loy CT, Sweeney MG, Davis MB, et al. Spinocerebellar ataxia type 17: extension of phenotype with putaminal rim hyperintensity on magnetic resonance imaging. Mov Disord 2005; 20: 1521-1523.
24. Toyoshima Y, Yamada M, Onodera O, et al. SCA17 homozygote showing Huntington's disease-like phenotype. Ann Neurol 2004; 55: 281-286.
25. Schneider SA, van De Warrenburg BP, Hughes TD, et al. Phenotypic homogeneity of the Huntington disease-like presentation in a SCA17 family. Neurology 2006; 67: 1701-1703.
26. Wild EJ, Mudanohwo EE, Sweeney MG, et al. Huntington's disease phenocopies are clinically and genetically heterogeneous. Mov Disord 2008; 23: 716-720.
27. Namekawa M, Takiyama Y, Ando Y, et al. Choreiform movements in spinocerebellar ataxia type 1. J Neurol Sci 2001; 187: 103-106.
28. Kameya T, Abe K, Aoki M, et al. Analysis of spinocerebellar ataxia type 1 (SCA1)-related CAG trinucleotide expansion in Japan. Neurology 1995; 45: 1587-1594.
29. Stevanin G, Hahn V, Lohmann E, et al. Mutation in the catalytic domain of protein kinase C gamma and extension of the phenotype associated with spinocerebellar ataxia type 14. Arch Neurol 2004; 61: 1242-1248.
30. van Swieten JC, Brusse E, de Graaf BM, et al. A mutation in the fibroblast growth factor 14 gene is associated with autosomal dominant cerebellar ataxia [corrected]. Am J Hum Genet 2003; 72: 191-199.
31. Ragothaman M, Sarangmath N, Chaudhary S, et al. Complex phenotypes in an Indian family with homozygous SCA2 mutations. Ann Neurol 2004; 55: 130-133.
32. Shan DE, Soong BW, Sun CM, Lee SJ, Liao KK, Liu RS. Spinocerebellar ataxia type 2 presenting as familial levodopa-responsive parkinsonism. Ann Neurol 2001; 50: 812-815.
33. Gwinn-Hardy K, Chen JY, Liu HC, et al. Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. Neurology 2000; 55: 800-805.
34. Lu CS, Wu Chou YH, Yen TC, Tsai CH, Chen RS, Chang HC. Dopa-responsive parkinsonism phenotype of spinocerebellar ataxia type 2. Mov Disord 2002; 17: 1046-1051.
35. Lu CS, Wu Chou YH, Kuo PC, Chang HC, Weng YH. The parkinsonian phenotype of spinocerebellar ataxia type 2. Arch Neurol 2004; 61: 35-38.
36. Charles P, Camuzat A, Benammar N, et al. Are interrupted SCA2 CAG repeat expansions responsible for parkinsonism? Neurology 2007; 69: 1970-1975.
37. Gwinn-Hardy K, Singleton A, O'suilleabhain P, et al. Spinocerebellar ataxia type 3 phenotypically resembling parkinson disease in a black family. Arch Neurol 2001; 58: 296-299.
38. Subramony SH, Hernandez D, Adam A, et al. Ethnic differences in the expression of neurodegenerative disease: Machado-Joseph disease in Africans and Caucasians. Mov Disord 2002; 17: 1068-1071.
39. Momeni P, Lu CS, Chou YH, et al. Taiwanese cases of SCA2 are derived from a single founder. Mov Disord 2005; 20: 1633-1636.
40. Kim JY, Kim SY, Kim JM, et al. Spinocerebellar ataxia type 17 mutation as a causative and susceptibility gene in parkinsonism. Neurology 2009; 72: 1385-1389.
41. Lin IS, Wu RM, Lee-Chen GJ, Shan DE, Gwinn-Hardy K. The SCA17 phenotype can include features of MSA-C, PSP and cognitive impairment. Parkinsonism Relat Disord 2007; 13: 246-249.
42. Nakamura K, Jeong SY, Uchihara T, et al. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet 2001; 10: 1441-1448.
43. Arpa J, Cuesta A, Cruz-Martinez A, Santiago S, Sarria J, Palau F. Clinical features and genetic analysis of a Spanish family with spinocerebellar ataxia 6. Acta Neurol Scand 1999; 99: 43-47.
44. Khan NL, Giunti P, Sweeney MG, et al. Parkinsonism and nigrostriatal dysfunction are associated with spinocerebellar ataxia type 6 (SCA6). Mov Disord 2005; 20: 1115-1119.
45. Klebe S, Durr A, Rentschler A, et al. New mutations in protein kinase Cgamma associated with spinocerebellar ataxia type 14. Ann Neurol 2005; 58: 720-729.
46. Kohira I, Ujike H, Katsu T, Ninomiya Y, Ohashi K. [A case of spinocerebellar ataxia type 6 with hypochondriasis and severe parkinsonism]. No To Shinkei 2001; 53: 1119-1122.
47. Mori N, Adachi Y, Takeshima T, Kashiwaya Y, Okada A, Nakashima K. Branched-chain amino acid therapy for spinocerebellar degeneration: a pilot clinical crossover trial. Intern Med 1999; 38: 401-406.
48. Schols L, Kruger R, Amoiridis G, Przuntek H, Epplen JT, Riess O. Spinocerebellar ataxia type 6: genotype and phenotype in German kindreds. J Neurol Neurosurg Psychiatry 1998; 64: 67-73.
49. O'Hearn E, Holmes SE, Calvert PC, Ross CA, Margolis RL. SCA-12: tremor with cerebellar and cortical atrophy is associated with a CAG repeat expansion. Neurology 2001; 56: 299-303.
50. Vuillaume I, Devos D, Schraen-Maschke S, et al. A new locus for spinocerebellar ataxia (SCA21) maps to chromosome 7p21.3-p15.1. Ann Neurol 2002; 52: 666-670.
51. Nirenberg MJ, Libien J, Vonsattel JP, Fahn S. Multiple system atrophy in a patient with the spinocerebellar ataxia 3 gene mutation. Mov Disord 2007; 22: 251-254.
52. Buhmann C, Bussopulos A, Oechsner M. Dopaminergic response in Parkinsonian phenotype of Machado-Joseph disease. Mov Disord 2003; 18: 219-221.
53. Infante J, Berciano J, Volpini V, et al. Spinocerebellar ataxia type 2 with levodopa-responsive parkinsonism culminating in motor neuron disease. Mov Disord 2004; 19: 848-852.
54. Wilkins A, Brown JM, Barker RA. SCA2 presenting as levodopa-responsive parkinsonism in a young patient from the United Kingdom: a case report. Mov Disord 2004; 19: 593-595.
55. Garcia Ruiz PJ, Mayo D, Hernandez J, Cantarero S, Ayuso C. Movement disorders in hereditary ataxias. J Neurol Sci 2002; 202: 59-64.
56. Knight MA, Gardner RJ, Bahlo M, et al. Dominantly inherited ataxia and dysphonia with dentate calcification: spinocerebellar ataxia type 20. Brain 2004; 127: 1172-1181.
57. Knight MA, Hernandez D, Diede SJ, et al. A duplication at chromosome 11q12.2-11q12.3 is associated with spinocerebellar ataxia type 20. Hum Mol Genet 2008; 17: 3847-3853.
58. Modi G, Modi M, Martinus I, Rodda J, Saffer D. The clinical and genetic characteristics of spinocerebellar ataxia type 7 (SCA 7) in three Black South African families. Acta Neurol Scand 2000; 101: 177-182.
59. Freund HJ, Barnikol UB, Nolte D, et al. Subthalamic-thalamic DBS in a case with spinocerebellar ataxia type 2 and severe tremor-a unusual clinical benefit. Mov Disord 2007; 22: 732-735.
60. Berciano J, Infante J, Garcia A, et al. Stiff man-like syndrome and generalized myokymia in spinocerebellar ataxia type 3. Mov Disord 2006; 21: 1031-1035.
61. Singhal S, Gontu V, Choudhary P, Auer D, Bajaj N. Spinocerebellar ataxia type 1 mimicking stiff person syndrome. Mov Disord 2009; 24: 2158-2160.
62. Schols L, Peters S, Szymanski S, et al. Extrapyramidal motor signs in degenerative ataxias. Arch Neurol 2000; 57: 1495-1500.
63. Abele M, Burk K, Laccone F, Dichgans J, Klockgether T. Restless legs syndrome in spinocerebellar ataxia types 1, 2, and 3. J Neurol 2001; 248: 311-314.
64. Boesch SM, Frauscher B, Brandauer E, Wenning GK, Poewe W, Hogl B. Restless legs syndrome and motor activity during sleep in spinocerebellar ataxia type 6. Sleep Med 2006; 7: 529-532.
65. van AN, Sinke RJ, Zwarts MJ, et al. Intermediate CAG repeat lengths (53, 54) for MJD/SCA3 are associated with an abnormal phenotype. Ann Neurol 2001; 49: 805-807.
66. LeDoux MS, Brady KA. Secondary cervical dystonia associated with structural lesions of the central nervous system. Mov Disord 2003; 18: 60-69.
67. Alarcon F, Tolosa E, Munoz E. Focal limb dystonia in a patient with a cerebellar mass. Arch Neurol 2001; 58: 1125-1127.
68. van Rootselaar AF, van der Salm SM, Bour LJ, et al. Decreased cortical inhibition and yet cerebellar pathology in 'familial cortical myoclonic tremor with epilepsy.' Mov Disord 2007; 22: 2378-2385.
69. Tijssen MA, Thom M, Ellison DW, et al. Cortical myoclonus and cerebellar pathology. Neurology 2000; 54: 1350-1356.
70. Koh KN, Lim BC, Hwang H, et al. Cerebellum can be a possible generator of progressive myoclonus. J Child Neurol 2009; 25: 728-731.
71. Liepert J, Wessel K, Schwenkreis P, et al. Reduced intracortical facilitation in patients with cerebellar degeneration. Acta Neurol Scand 1998; 98: 318-323.
72. Schwenkreis P, Tegenthoff M, Witscher K, et al. Motor cortex activation by transcranial magnetic stimulation in ataxia patients depends on the genetic defect. Brain 2002; 125: 301-309.
73. Estrada R, Galarraga J, Orozco G, Nodarse A, Auburger G. Spinocerebellar ataxia 2 (SCA2): morphometric analyses in 11 autopsies. Acta Neuropathol 1999; 97: 306-310.
74. Rolfs A, Koeppen AH, Bauer I, et al. Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17). Ann Neurol 2003; 54: 367-375.
75. Rub U, Brunt ER, Deller T. New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado-Joseph disease). Curr Opin Neurol 2008; 21: 111-116.
76. Riess O, Rub U, Pastore A, Bauer P, Schols L. SCA3: neurological features, pathogenesis and animal models. Cerebellum 2008; 7: 125-137.
77. Durr A, Smadja D, Cancel G, et al. Autosomal dominant cerebellar ataxia type I in Martinique (French West Indies). Clinical and neuropathological analysis of 53 patients from three unrelated SCA2 families. Brain 1995; 118: 1573-1581.
78. Durr A, Stevanin G, Cancel G, et al. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol 1996; 39: 490-499.
79. Boesch SM, Donnemiller E, Muller J, et al. Abnormalities of dopaminergic neurotransmission in SCA2: a combined 123I-betaCIT and 123I-IBZM SPECT study. Mov Disord 2004; 19: 1320-1325.
80. Wullner U, Reimold M, Abele M, et al. Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6. Arch Neurol 2005; 62: 1280-1285.
81. Furtado S, Farrer M, Tsuboi Y, et al. SCA-2 presenting as parkinsonism in an Alberta family: clinical, genetic, and PET findings. Neurology 2002; 59: 1625-1627.
82. Varrone A, Salvatore E, De MG, et al. Reduced striatal [123 I]FP-CIT binding in SCA2 patients without parkinsonism. Ann Neurol 2004; 55: 426-430.
83. Minnerop M, Joe A, Lutz M, et al. Putamen dopamine transporter and glucose metabolism are reduced in SCA17. Ann Neurol 2005; 58: 490-491.
84. Salvatore E, Varrone A, Sansone V, et al. Characterization of nigrostriatal dysfunction in spinocerebellar ataxia 17. Mov Disord 2006; 21: 872-875.
85. Gierga K, Schelhaas HJ, Brunt ER, et al. Spinocerebellar ataxia type 6 (SCA6): neurodegeneration goes beyond the known brain predilection sites. Neuropathol Appl Neurobiol 2009; 35: 515-527.
86. Kim JM, Lee JY, Kim HJ, et al. The wide clinical spectrum and nigrostriatal dopaminergic damage in spinocerebellar ataxia type 6. J Neurol Neurosurg Psychiatry 2010; 81: 529-532.
87. De Michele G, Maltecca F, Carella M, et al. Dementia, ataxia, extrapyramidal features, and epilepsy: Phenotype spectrum in two Italian families with spinocerebellar ataxia type 17. Neurol Sci 2003; 24: 166-167.
88. Robitaille Y, Lopes-Cendes I, Becher M, Rouleau G, Clark AW. The neuropathology of CAG repeat diseases: review and update of genetic and molecular features. Brain Pathol 1997; 7: 901-926.
89. Schulz JB, Borkert J, Wolf S, et al. Visualization, quantification and correlation of brain atrophy with clinical symptoms in spinocerebellar ataxia types 1, 3 and 6. Neuroimage 2010; 49: 158-168.
90. Reimold M, Globas C, Gleichmann M, et al. Spinocerebellar ataxia type 1, 2, and 3 and restless legs syndrome: striatal dopamine D2 receptor status investigated by [11C]raclopride positron emission tomography. Mov Disord 2006; 21: 1667-1673.
91. Modoni A, Contarino MF, Bentivoglio AR, et al. Prevalence of spinocerebellar ataxia type 2 mutation among Italian Parkinsonian patients. Mov Disord 2007; 22: 324-327.
92. Simon-Sanchez J, Hanson M, Singleton A, et al. Analysis of SCA-2 and SCA-3 repeats in Parkinsonism: evidence of SCA-2 expansion in a family with autosomal dominant Parkinson's disease. Neurosci Lett 2005; 382: 191-194.
93. Shan DE, Liu RS, Sun CM, Lee SJ, Liao KK, Soong BW. Presence of spinocerebellar ataxia type 2 gene mutation in a patient with apparently sporadic Parkinson's disease: clinical implications. Mov Disord 2004; 19: 1357-1360.
94. Wu YR, Lin HY, Chen CM, et al. Genetic testing in spinocerebellar ataxia in Taiwan: expansions of trinucleotide repeats in SCA8 and SCA17 are associated with typical Parkinson's disease. Clin Genet 2004; 65: 209-214.
95. Wang JL, Xiao B, Cui XX, et al. Analysis of SCA2 and SCA3/MJD repeats in Parkinson's disease in mainland China: genetic, clinical, and positron emission tomography findings. Mov Disord 2009; 24: 2007-2011.
96. Kim JM, Hong S, Kim GP, et al. Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism. Arch Neurol 2007; 64: 1510-1518.
97. Tan EK, Tong J, Pavanni R, Wong MC, Zhao Y. Genetic analysis of SCA 2 and 3 repeat expansions in essential tremor and atypical Parkinsonism. Mov Disord 2007; 22: 1971-1974.
98. Wu YR, Chen IC, Soong BW, et al. SCA8 repeat expansion: large CTA/CTG repeat alleles in neurological disorders and functional implications. Hum Genet 2009; 125: 437-444.
99. Grundmann K, Laubis-Herrmann U, Dressler D, et al. Mutation at the SCA17 locus is not a common cause of primary dystonia. J Neurol 2004; 251: 1232-1234.
100. Nicoletti G, Annesi G, Carrideo S, et al. Familial essential tremor is not associated with SCA-12 mutation in southern Italy. Mov Disord 2002; 17: 837-838.
101. De Rosa A, Striano P, Barbieri F, et al. Suppression of myoclonus in SCA2by Piracetam. Mov Disord 2006; 21: 116-118.
102. Wu YR, Lee-Chen GJ, Lang AE, Chen CM, Lin HY, Chen ST. Dystonia as a presenting sign of spinocerebellar ataxia type 1. Mov Disord 2004; 19: 586-587.
103. Hernandez D, Hanson M, Singleton A, et al. Mutation at the SCA17 locus is not a common cause of parkinsonism. Parkinsonism Relat Disord 2003; 9: 317-320.
104. Kock N, Muller B, Vieregge P, et al. Role of SCA2 mutations in early- and late-onset dopa-responsive parkinsonism. Ann Neurol 2002; 52: 257-258.
105. Lim SW, Zhao Y, Chua E, et al. Genetic analysis of SCA2, 3 and 17 in idiopathic Parkinson's disease. Neurosci Lett 2006; 403: 11-14.
106. Lin CH, Hwu WL, Chiang SC, Tai CH, Wu RM. Lack of mutations in spinocerebellar ataxia type 2 and 3 genes in a Taiwanese (ethnic Chinese) cohort of familial and early-onset parkinsonism. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 434-438.
107. Payami H, Nutt J, Gancher S, et al. SCA2 may present as levodopa-responsive parkinsonism. Mov Disord 2003; 18: 425-429.
108. Svetel M, Djarmati A, Dragasevic N, et al. SCA2 and SCA3 mutations in young-onset dopa-responsive parkinsonism. Eur J Neurol 2003; 10: 597.
109. Park SS, Jeon BS. Spinocerebellar ataxia type 12 was not found in Korean Parkinsonian patients. Can J Neurol Sci 2008; 35: 488-490.
110. Sulek-Piatkowska A, Krysa W, Zdzienicka E, et al. Searching for mutation in the JPH3, ATN1 and TBP genes in Polish patients suspected of Huntington's disease and without mutation in the IT15 gene. Neurol Neurochir Pol 2008; 42: 203-209.
111. Costa MC, Teixeira-Castro A, Constante M, et al. Exclusion of mutations in the PRNP, JPH3, TBP, ATN1, CREBBP, POU3F2 and FTL genes as a cause of disease in Portuguese patients with a Huntington-like phenotype. J Hum Genet 2006; 51: 645-651.